StemGen Stock

StemGen FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of StemGen (SGNI) as of Aug 13, 2026 is 32.60 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 15.81 % — a change of 106.15% (higher).

FCF Conversion

32.60 %

YoY

106.15%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of StemGen is 2026 32.60 % . FCF Conversion Rate (FCF/EBITDA) of StemGen was 2025 15.81 % . It decreases by 106.15% higher compared to the previous year.
Access this data via the Eulerpool API

StemGen Stock analysis

What does StemGen do? StemGen Inc. is a biotechnology company founded in 2005, headquartered in California, USA. The company specializes in the development and research of stem cell products for medical purposes. StemGen Inc. is one of the leading companies in the field of stem cell research. StemGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemGen stock

FCF Conversion Rate (FCF/EBITDA) of StemGen is 32.60 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of StemGen changed from 15.81 % to 32.60 %, representing a 106.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) StemGen since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s StemGen with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — StemGen

All Key Metrics — StemGen